Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orexigen Empatic That Results For Second Obesity Drug Will Help Lure Partner

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Given the potential to cause birth defects, Orexigen's obesity drug Empatic is probably not suited for the masses. Still, executives say the promising combo pill could complement the company's better known obesity agent Contrave and help bring a partner on board

You may also be interested in...



Vivus Obesity Pill Scores With Phase III Data, But Still Faces Major Market Hurdles

Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."

Orexigen Starts Partnership Talks On Obesity Drug Contrave

Firm stresses Phase III efficacy results will pass muster with FDA.

Sanofi Withdraws Zimulti NDA For Weight Loss

Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel